PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy

被引：30

作者：

Matsumoto, Koji ^{[1
,2
]}

Nishimura, Meiko ^{[1
,2
]}

Onoe, Takuma ^{[1
,2
]}

Sakai, Hideki ^{[1
]}

Urakawa, Yusaku ^{[2
]}

Onda, Takashi ^{[3
]}

Yaegashi, Nobuo ^{[4
]}

机构：

[1] Hyogo Canc Ctr, Div Med Oncol, Akashi, Hyogo, Japan

[2] Hyogo Canc Ctr, Div Clin Genet, Akashi, Hyogo, Japan

[3] Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan

[4] Tohoku Univ, Dept Gynecol & Obstet, Sendai, Miyagi, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 49卷 / 08期

关键词：

PARP inhibitors; BRCA wild type; HRD; LOH; genetic counseling; MAINTENANCE THERAPY; BREAST-CANCER; DOUBLE-BLIND; OLAPARIB; MUTATIONS; RISK; GERMLINE; WOMEN;

D O I：

10.1093/jjco/hyz090

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After a brief summary of the current status of poly-ADP ribose polymerase (PARP) inhibitors for ovarian cancer, we summarize the current status of PARP inhibitors for BRCA wild type ovarian cancer, especially regarding gene alterations other than BRCA, homologous recombination deficiency (HRD), and combinations. Discussion of gene alterations other than BRCA include the results of multiple gene panels studying homologous recombination repair deficiency genes and cancer susceptibility genes, and influences of these alterations on efficacy of PARP inhibitors and cancer susceptibility. Discussions of HRD include the results of phase three trials using HRD assay, the definition of HRD assays, and the latest assays. Discussions of combinations include early phase trial results and ongoing trials combining PARP inhibitors with immune checkpoint inhibitors, anti-angiogenic agents, and triplets.

引用

页码：703 / 707

页数：5

共 26 条

[11] The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer [J].

Huang, Jing ;

Wang, Lei ;

Cong, Zhongyi ;

Amoozgar, Zohreh ;

Kiner, Evgeny ;

Xing, Deyin ;

Orsulic, Sandra ;

Matulonis, Ursula ;

Goldberg, Michael S. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 463 (04) :551-556

[12] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].

Kaufman, Bella ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Steiner, Mariana ;

Loman, Niklas ;

Bowen, Karin ;

Fielding, Anitra ;

Domchek, Susan M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250

[13] Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab [J].

Konstantinopoulos, P. A. ;

Munster, P. ;

Forero-Torez, A. ;

Holloway, R. W. ;

Schwartzberg, L. ;

Matulonis, U. A. ;

Wang, J. ;

Guo, W. ;

Dezube, B. ;

Vinayak, S. .

GYNECOLOGIC ONCOLOGY, 2018, 149 :246-246

[14] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[15] Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer [J].

Liu, J. F. ;

Barry, W. T. ;

Birrer, M. ;

Lee, J-M ;

Buckanovich, R. J. ;

Fleming, G. F. ;

Rimel, B. J. ;

Buss, M. K. ;

Nattam, S. R. ;

Hurteau, J. ;

Luo, W. ;

Curtis, J. ;

Whalen, C. ;

Kohn, E. C. ;

Ivy, S. P. ;

Matulonis, U. A. .

ANNALS OF ONCOLOGY, 2019, 30 (04) :551-557

[16] Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J].

Liu, Joyce F. ;

Barry, William T. ;

Birrer, Michael ;

Lee, Jung-Min ;

Buckanovich, Ronald J. ;

Fleming, Gini F. ;

Rimel, B. J. ;

Buss, Mary K. ;

Nattam, Sreenivasa ;

Hurteau, Jean ;

Luo, Weixiu ;

Quy, Philippa ;

Whalen, Christin ;

Obermayer, Lisa ;

Lee, Hang ;

Winer, Eric P. ;

Kohn, Elise C. ;

Ivy, S. Percy ;

Matulonis, Ursula A. .

LANCET ONCOLOGY, 2014, 15 (11) :1207-1214

[17] Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto [J].

Loibl, S. ;

Weber, K. E. ;

Timms, K. M. ;

Elkin, E. P. ;

Hahnen, E. ;

Fasching, P. A. ;

Lederer, B. ;

Denkert, C. ;

Schneeweiss, A. ;

Braun, S. ;

Salat, C. T. ;

Rezai, M. ;

Blohmer, J. U. ;

Zahm, D. M. ;

Jackisch, C. ;

Gerber, B. ;

Klare, P. ;

Kuemmel, S. ;

Schem, C. ;

Paepke, S. ;

Schmutzler, R. ;

Rhiem, K. ;

Penn, S. ;

Reid, J. ;

Nekljudova, V. ;

Hartman, A-R ;

von Minckwitz, G. ;

Untch, M. .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2341-2347

[18] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer [J].

Mirza, M. R. ;

Monk, B. J. ;

Herrstedt, J. ;

Oza, A. M. ;

Mahner, S. ;

Redondo, A. ;

Fabbro, M. ;

Ledermann, J. A. ;

Lorusso, D. ;

Vergote, I. ;

Ben-Baruch, N. E. ;

Marth, C. ;

Madry, R. ;

Christensen, R. D. ;

Berek, J. S. ;

Dorum, A. ;

Tinker, A. V. ;

du Bois, A. ;

Gonzalez-Martin, A. ;

Follana, P. ;

Benigno, B. ;

Rosenberg, P. ;

Gilbert, L. ;

Rimel, B. J. ;

Buscema, J. ;

Balser, J. P. ;

Agarwal, S. ;

Matulonis, U. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) :2154-2164

[19] Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Moore, K. ;

Colombo, N. ;

Scambia, G. ;

Kim, B. -G. ;

Oaknin, A. ;

Friedlander, M. ;

Lisyanskaya, A. ;

Floquet, A. ;

Leary, A. ;

Sonke, G. S. ;

Gourley, C. ;

Banerjee, S. ;

Oza, A. ;

Gonzalez-Martin, A. ;

Aghajanian, C. ;

Bradley, W. ;

Mathews, C. ;

Liu, J. ;

Lowe, E. S. ;

Bloomfield, R. ;

DiSilvestro, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) :2495-2505

[20] Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas [J].

Pennington, Kathryn P. ;

Walsh, Tom ;

Harrell, Maria I. ;

Lee, Ming K. ;

Pennil, Christopher C. ;

Rendi, Mara H. ;

Thornton, Anne ;

Norquist, Barbara M. ;

Casadei, Silvia ;

Nord, Alexander S. ;

Agnew, Kathy J. ;

Pritchard, Colin C. ;

Scroggins, Sheena ;

Garcia, Rochelle L. ;

King, Mary-Claire ;

Swisher, Elizabeth M. .

CLINICAL CANCER RESEARCH, 2014, 20 (03) :764-775

← 1 2 3 →